Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis.
Vibeke StrandLixia ZhangAlix ArnaudErin Connolly-StrongSam AsgarianJohanna B WithersPublished in: Expert opinion on biological therapy (2022)
RA treatment selection informed by MSRC test results improves clinical outcomes in real-world care and offers improvements in efficiency of healthcare spending.